A drug that blocks the action of the enzyme Cdk5 could
substantially reduce brain damage if administered shortly after a stroke, UT
Southwestern Medical Center research suggests.
The findings, reported in the June 11 issue of the Journal
of Neuroscience, determined in rodent models that aberrant Cdk5 activity causes
nerve cell death during stroke.